A Single Arm, Phase II Study of TNFerade Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer

Trial Profile

A Single Arm, Phase II Study of TNFerade Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Apr 2012

At a glance

  • Drugs Golnerminogene pradenovec (Primary) ; Cisplatin; Fluorouracil
  • Indications Oesophageal cancer
  • Focus Therapeutic Use
  • Sponsors GenVec
  • Most Recent Events

    • 26 Apr 2012 Results have been reported in Gastrointestinal Endoscopy.
    • 11 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jan 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top